Millot, FrédéricGuilhot, JoëlleSuttorp, MeinolfSedlacek, PetrDe Bont, EvelineLi, Chi KongKalwak, KrzysztofLausen, BirgitteCulic, SrdjanaDworzak, MichaelKaiserova, EmiliaDe Moerloose, BarbaraRoula, FarahBiondi, AndreaBaruchel, André2022-12-262022-12-262017-08-17Millot, F. vd. (2017). ''Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents''. Haematologica, 102(10), 1704-1708.0390-6078https://doi.org/10.3324/haematol.2017.170035https://haematologica.org/article/view/8218http://hdl.handle.net/11452/30082The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%-94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%-99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%-98%), 88% (95% CI: 76%-95%) and 67% (95% CI: 48%-81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P < 0.0001, overall). The EUTOS Long-Term Survival score showed better differentiation of progression-free survival than the Sokal (<45 years), Euro and EUTOS scores in children and adolescents with chronic myeloid leukemia and should be considered in therapeutic algorithms.eninfo:eu-repo/semantics/openAccessHematologyChronic granulocytic-leukemiaChronic myelogenous leukemiaPopulation-based registry2904 cml patientsEuropean leukemianetMolecular responseInterferon-alphaYounger patientsRandomized cmlImatinibAdolescentAntineoplastic combined chemotherapy protocolsChildChild, preschoolDisease progressionDisease-free survivalFemaleFollow-up studiesHumansInfantLeukemia, myelogenous, chronic, BCR-ABL positiveMalePrognosisRegistriesTreatment outcomeArticle0004119642000222-s2.0-85030315435170417081021028838993HematologyChronic Myeloid Leukemia; Imatinib; Protein Tyrosine Kinase InhibitorImatinibAntineoplastic agentAcute graft versus host diseaseAdolescentAdultArticleCancer prognosisCancer survivalChildChronic myeloid leukemiaEUTOS scoreFemaleHemoglobin blood levelHigh risk patientHumanInfantInfectionIntermediate risk patientLeukocyte countLong term survival scoreLow risk patientMajor clinical studyMaleOverall survivalPreschool childPrognostic discriminationProgression free survivalSchool childScoring systemSpleen sizeChronic myeloid leukemiaDisease exacerbationDisease free survivalFollow upMortalityPrognosisRegisterTreatment outcome